Business Trends– category –
-
Avidity Biosciences Leads Muscle Disease Therapy with Antibody-Oligonucleotide Conjugates (AOCs): DM1 HARBINGER™ Trial Advances to Phase 3
Bitget Global Overview Avidity Biosciences is a leading company in Antibody-Oligonucleotide Conjugates (AOCs), developing novel RNA therapeutics for muscle diseases. Its lead candidate, delpacibart etedesiran (AOC 1001), is progressing i... -
Contract Organizations’ Pivotal Role in Lentiviral Manufacturing Accelerates Gene Therapy Commercialization
MAI CDMO Global Overview This article highlights the essential role of Contract Development and Manufacturing Organizations (CDMOs) in lentiviral vector manufacturing, crucial for gene and cell therapies like CAR-T. Lentiviral vector pro... -
Silexion Therapeutics Initiates GMP Manufacturing for KRAS-Driven Cancer siRNA Therapy SIL204, Secures Phase 2/3 Trial Approval
Manila Times (via GlobeNewswire) ケイマン諸島 Overview Silexion Therapeutics has commenced GMP clinical batch manufacturing for SIL204, its next-generation siRNA therapeutic targeting mutated KRAS oncogenes. Concurrently, the company rec... -
Zealand Pharma Advances Obesity Pipeline with Phase 3 Progress, Leveraging Roche and Boehringer Ingelheim Partnerships
WhaleWisdom Global Overview Zealand Pharma, in partnership with Roche, is progressing its obesity drug candidate petrelintide into Phase 3 trials following favorable Phase 2 data on weight loss and tolerability. Separately, Boehringer In... -
siRNA Therapeutics: Advancements in Chemical Modification and Targeted Delivery Expand Clinical Horizons Beyond the Liver
MDPI Global Overview siRNA therapeutics are achieving significant clinical success driven by sophisticated chemical modifications and robust delivery systems. GalNAc conjugates have become the gold standard for liver-targeted therapies, ... -
Bora Group Acquires MacroGenics’ Manufacturing Operations, Expanding US Biopharmaceutical CDMO Platform
Manufacturing Chemist USA Overview Bora Group announced the acquisition of MacroGenics' GMP manufacturing and CDMO business for $122.5 million, which includes a biopharmaceutical drug substance manufacturing facility in Rockville, Maryla... -
Solid-State EV Battery Roadmaps Converge: Pilot Production in 2026, Consumer Availability Expected by Late 2027
EVドライブナビ Global Overview The year 2026 is marked as a period of intensified pilot production and trial integration for all-solid-state batteries (ASSBs), with consumer-ready ASSB EVs anticipated from late 2027 to 2028. Chinese manu... -
ProLogium Revolutionizes Solid-State Batteries with ‘All-Inorganic Super Flow’ Electrolyte, Achieves 5-Minute Fast Charge and Cost-Efficient Mass Production
owl - note Taiwan Overview Taiwan's ProLogium Technology is breaking through key barriers to solid-state battery commercialization with its proprietary 'All-Inorganic Super Flow' solid electrolyte technology. This innovation overcomes th... -
Toyota Accelerates Solid-State EV Development for 2028 Launch, Targets 5-Minute Charge and 1,200-Mile Range
YouTube (動画コンテンツの要約) Japan Overview Toyota is intensifying its mass production efforts for all-solid-state battery (ASSB) EVs, targeting market introduction between 2027 and 2028. The company has set ambitious performance goals... -
QuantumScape Director Sells Shares Valued at $212,868 Under Pre-Arranged Trading Plan
Investing.com JP USA Overview QuantumScape Director Jeffrey B. Straubel reportedly sold 27,106 shares of Class A common stock for approximately $212,868 on May 12, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trad...
